Resources Repository
-
BookPublication 2003WHO Guide to Cost-Effectiveness Analysis
This 2003 guide provides a method of assessing the cost-effectiveness of health interventions for an …
This 2003 guide provides a method of assessing the cost-effectiveness of health interventions for an international audience. The authors aim to inform the policy maker and to maximize the generalizability of results across settings. Part I begins with a description of cost-effectiveness analysis. It then considers issues relating to study design, estimating costs, assessing health effects, discounting, uncertainty and sensitivity analysis, and reporting results. Part II provides examples to illustrate the principles in Part I. Detailed discussions…
Cost-Effectiveness Analysis | Health Outcomes | Priority Setting/Ethics | Costing Methods | Evidence Synthesis | Mathematical Models | Health Systems | Health/Medicine | Global -
BookPublication 1996Cost-Effectiveness in Health and Medicine, 1st Edition
In 1993, the US Public Health Service convened a panel of 13 nongovernment scientists and …
In 1993, the US Public Health Service convened a panel of 13 nongovernment scientists and scholars with expertise in economics, clinical medicine, ethics, and statistics to review the state of cost-effectiveness analysis and to develop recommendations for its conduct and use in health and medicine. Publishing their results in 1996, they proposed the most explicit set of guidelines (together with their rationale) ever defined on the conduct of CEAs. The panel recommended analysts include a "reference-case"…
Cost-Effectiveness Analysis | Health Outcomes | Preferences/Values | Priority Setting/Ethics | Costing Methods | Evidence Synthesis | Value of Information | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine | North America -
ReviewPublication 1982Decision Analysis: An Overview
This article, written for the non-decision analyst, describes what decision analysis is, what it can …
This article, written for the non-decision analyst, describes what decision analysis is, what it can and cannot do, why one should care to do this, and how one does it. Keeney describes decision analysis as "a formalization of common sense for decision problems which are too complex for informal use of common sense." He provides a more technical definition also, describing decision analysis as "a philosophy, articulated by a set of logical axioms, and a methodology…
Decision Theory | Decision Analysis | Preferences/Values | Policy/Regulation | Business/Industry | Economics/Finance | Energy/Engineering | Government/Law | Health/Medicine | Military/Defense | Science/Technology -
BookPublication 1978Swine Flu Affair: Decision-Making on a Slippery Disease
This report from the Institute of Medicine, The Swine Flu Affair: Decision-Making on a Slippery …
This report from the Institute of Medicine, The Swine Flu Affair: Decision-Making on a Slippery Disease, was written to review and critique the decisions made around the 1976 swine flu threat. In 1976, a small group of soldiers at Fort Dix were infected with a swine flu virus that was deemed similar to the virus responsible for the great 1918-19 world-wide flu pandemic. The U.S. government initiated an unprecedented effort to immunize every American against…
Risk Analysis | Decision Analysis | Infectious Diseases | Health Systems | Policy/Regulation | Health/Medicine | Science/Technology | North America -
ReviewPublication 2024Cost-Effectiveness of Newer Pharmacologic Treatments in Adults with Type 2 Diabetes: Systematic Review of Cost-Effectiveness Studies for the American College of Physicians
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in …
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in the United States. The study screened nonindustry-funded cost-effectiveness analyses (CEAs) conducted from 2010 to 2023, focusing on estimating cost per quality-adjusted life-year (QALY) gained. Nine CEAs met the criteria, evaluating medications such as glucagon-like peptide-1 agonists (GLP1a), dipeptidyl peptidase-4 inhibitors (DPP4i), and sodium–glucose cotransporter-2 inhibitors (SGLT2i), among others. Comparisons were made against metformin, sulfonylureas, neutral protamine Hagedorn (NPH) insulin, and…
Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine | North America -
ReportPublication 2022Investment Case for New Tuberculosis Vaccines
Investing more financial resources to accelerate scientific progress toward an effective tuberculosis (TB) vaccine will …
Investing more financial resources to accelerate scientific progress toward an effective tuberculosis (TB) vaccine will save lives, fight antimicrobial resistance, advance health equity, improve economic growth, and bring a substantial return on investment. This World Health Organization (WHO) report describes the full value proposition for new TB vaccines. These analyses articulate the broader economic impacts of new TB vaccines to guide global stakeholders when making investment decisions for novel TB vaccines and to plan for…
Cost-Effectiveness Analysis | Infectious Diseases | Economics/Finance | Health/Medicine | Global -
ReviewPublication 2022Systematic Review of Economic Evaluations of COVID-19 Interventions: Non-Health Impacts and Distributional Issues
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether …
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether they incorporated non-health impacts and distributional concerns. Among the 70 articles included, more than half (56%) included at least one non-health impact, although only 21% incorporated non-economic consequences. Only 17% examined subgroups of interest. The median ICER for the entire sample was $67,000/quality-adjusted life-year (QALY) (interquartile range [IQR] $9000-$893,000/QALY). Interventions including a pharmaceutical component yielded a median ICER of $93,000/QALY (IQR…
Cost-Effectiveness Analysis | Evidence Synthesis | Infectious Diseases | Social Determinants | Culture/Society | Economics/Finance | Health/Medicine | North America -
ReportPublication 2021Valuing COVID-19 Mortality and Morbidity Risks
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk …
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk reductions that builds on the U.S. Department of Health and Human Services (HHS) Guidelines for Regulatory Impact Analysis. They review the differences between COVID-19 mortality risks and the types of risks that are more commonly studied, and find that the impacts of these differences on the value of mortality risk reductions (the value per statistical life, VSL) are uncertain. They…
Benefit-Cost Analysis | Preferences/Values | Infectious Diseases | Policy/Regulation | Government/Law | North America -
BookPublication 2022Prioritarianism in Practice
This book describes the application of prioritarianism, a philosophical approach that gives extra weight to …
This book describes the application of prioritarianism, a philosophical approach that gives extra weight to the well-being of those who are worse off. In welfare economics, it can be implemented in the form of a prioritarian social welfare function (SWF). The SWF framework, unlike benefit-cost analysis, uses interpersonally comparable well-being numbers as the foundation for policy assessment. The book illustrates the application of this approach by an international network of scholars, to advance our understanding…
Benefit-Cost Analysis | Graduate